Aethlon Medical (AEMD) Financials

Aethlon Medical logo
$5.46 +0.62 (+12.81%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$5.42 -0.04 (-0.64%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Aethlon Medical

Annual Income Statements for Aethlon Medical

This table shows Aethlon Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
-4.87 -7.28 -5.68 -6.19 -6.37 -7.89 -10 -12 -12 -13 -7.15
Consolidated Net Income / (Loss)
-4.96 -7.31 -5.70 -6.22 -6.38 -7.89 -10 -12 -12 -13 -7.15
Net Income / (Loss) Continuing Operations
-4.96 -7.31 -5.70 -6.22 -6.38 -7.89 -10 -12 -12 -13 -7.15
Total Pre-Tax Income
-4.96 -7.31 -5.70 -6.22 -6.38 -7.89 -10 -12 -12 -13 -7.15
Total Operating Income
-4.38 -6.10 -4.83 -6.00 -5.93 -7.89 -10 -12 -13 -9.34 -7.29
Total Gross Profit
0.89 0.39 0.00 -2.85 -1.65 -2.80 -4.33 0.57 -5.21 -3.87 -2.79
Total Revenue
0.89 0.39 0.00 0.23 0.65 0.66 0.29 0.57 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 3.08 2.30 3.45 4.63 0.00 5.21 3.87 2.79
Operating Cost of Revenue
- - - 3.08 2.30 3.45 4.63 - 5.21 3.87 2.79
Total Operating Expenses
5.27 6.49 4.83 3.15 4.28 5.10 6.09 12 7.43 5.47 4.51
Selling, General & Admin Expense
3.19 3.01 2.35 3.15 4.28 5.10 6.09 8.03 7.43 5.47 4.51
Total Other Income / (Expense), net
-0.57 -1.21 -0.87 -0.22 -0.45 0.00 0.00 -0.13 0.43 -4.05 0.14
Interest & Investment Income
- - - - - - 0.00 0.01 0.45 0.30 0.16
Other Income / (Expense), net
0.00 -0.35 -0.13 0.00 0.05 - 0.00 -0.14 -0.02 -4.34 -0.02
Basic Earnings per Share
($0.66) ($0.94) ($0.10) ($5.13) ($1.87) ($0.65) - ($5.86) ($38.87) ($85.77) ($10.61)
Weighted Average Basic Shares Outstanding
7.39M 7.76M 12.32M 1.21M 3.41M 12.09M 14.76M 2.05M 314.10K 156.09K 673.95K
Diluted Earnings per Share
($0.66) ($0.94) ($0.10) ($5.13) ($1.87) ($0.65) - ($5.86) ($38.87) ($85.77) ($10.61)
Weighted Average Diluted Shares Outstanding
7.39M 7.76M 12.32M 1.21M 3.41M 12.09M 14.76M 2.05M 314.10K 156.09K 673.95K
Weighted Average Basic & Diluted Shares Outstanding
7.39M 7.76M 12.32M 1.21M 3.41M 12.09M 14.76M 24.77M 13.90M 2.59M 2.37M

Quarterly Income Statements for Aethlon Medical

This table shows Aethlon Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
-3.03 -3.47 -2.43 -2.57 -2.81 -1.75 -6.25 -1.76 -1.49 -2.02 -1.88
Consolidated Net Income / (Loss)
-3.03 -3.47 -2.43 -2.57 -2.81 -1.75 -6.25 -1.76 -1.49 -2.02 -1.88
Net Income / (Loss) Continuing Operations
-3.04 -3.46 -2.43 -2.57 -2.80 -1.75 -6.26 -1.76 -1.49 -2.02 -1.88
Total Pre-Tax Income
-3.04 -3.46 -2.43 -2.57 -2.80 -1.75 -6.26 -1.76 -1.49 -2.02 -1.88
Total Operating Income
-3.18 -3.57 -2.49 -2.62 -2.90 -1.81 -2.00 -1.79 -1.51 -2.06 -1.93
Total Gross Profit
-1.19 -1.92 -0.97 -1.25 -1.37 -0.62 -0.63 0.00 -0.59 -0.99 -1.21
Total Cost of Revenue
1.19 1.92 0.97 1.25 1.37 0.62 0.63 0.00 0.59 0.99 1.21
Total Operating Expenses
1.98 1.65 1.51 1.37 1.53 1.19 1.38 1.79 0.92 1.07 0.72
Selling, General & Admin Expense
1.98 1.65 1.51 1.37 1.53 1.19 1.38 1.21 0.92 1.07 1.30
Total Other Income / (Expense), net
0.14 0.11 0.05 0.05 0.10 0.06 -4.25 0.03 0.02 0.04 0.05
Basic Earnings per Share
($1.22) ($1.37) ($7.72) ($2.76) ($16.11) ($10.05) ($40.07) ($0.85) ($3.74) ($2.45) ($2.80)
Weighted Average Basic Shares Outstanding
2.48M 2.52M 314.10K 932.25K 174.22K 174.53K 156.09K 2.08M 397.51K 823.13K 673.95K
Diluted Earnings per Share
($1.22) ($1.37) ($7.72) ($2.76) ($16.11) ($10.05) ($40.07) ($0.85) ($3.74) ($2.45) ($2.80)
Weighted Average Diluted Shares Outstanding
2.48M 2.52M 314.10K 932.25K 174.22K 174.53K 156.09K 2.08M 397.51K 823.13K 673.95K
Basic & Diluted Earnings per Share
- - ($7.72) - - - ($40.07) - - - ($2.80)
Weighted Average Basic & Diluted Shares Outstanding
2.49M 2.62M 13.90M 13.94M 13.96M 14.46M 2.59M 2.60M 761.32K 1.32M 2.37M

Annual Cash Flow Statements for Aethlon Medical

This table details how cash moves in and out of Aethlon Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents
1.27 -0.01 5.41 -3.15 5.78 10 7.25 -2.54 -9.09 0.07 -0.47
Net Cash From Operating Activities
-4.33 -3.33 -3.91 -4.29 -5.20 3.14 -9.77 -11 -10 -7.65 -7.00
Net Cash From Continuing Operating Activities
-4.33 -3.33 -3.91 -4.29 -5.20 3.14 -9.77 -11 -10 -7.65 -7.00
Net Income / (Loss) Continuing Operations
-4.96 -7.31 -5.70 -6.22 -6.38 -7.89 -10 -12 -12 -13 -7.15
Consolidated Net Income / (Loss)
-4.96 -7.31 -5.70 -6.22 -6.38 -7.89 -10 -12 -12 -13 -7.15
Depreciation Expense
0.04 0.03 0.04 0.03 0.03 0.04 0.12 0.24 0.36 0.34 0.32
Non-Cash Adjustments To Reconcile Net Income
0.20 3.37 1.80 1.34 0.45 11 0.78 1.22 1.24 5.31 0.57
Changes in Operating Assets and Liabilities, net
-0.13 0.01 -0.29 0.33 0.34 0.31 -0.25 0.07 0.48 0.09 -0.74
Net Cash From Investing Activities
-0.01 -0.02 -0.02 0.00 -0.15 -0.06 -0.35 -0.94 -0.25 0.00 -0.00
Net Cash From Continuing Investing Activities
-0.01 -0.02 -0.02 0.00 -0.15 -0.06 -0.35 -0.94 -0.25 0.00 -0.00
Purchase of Property, Plant & Equipment
-0.01 - -0.02 0.00 -0.15 -0.06 -0.35 -0.94 -0.25 0.00 -0.00
Net Cash From Financing Activities
5.61 3.34 9.35 1.15 11 7.13 17 8.91 1.29 7.73 6.52
Net Cash From Continuing Financing Activities
5.61 3.34 9.35 1.15 11 7.13 17 8.91 1.29 7.73 6.52
Repurchase of Common Equity
0.00 - -0.28 - - - - - - -1.16 -1.09
Issuance of Common Equity
5.61 2.76 9.63 1.34 12 7.26 17 8.93 1.32 4.70 6.90
Other Financing Activities, net
- - - -0.19 -0.04 -0.13 -0.09 -0.01 -0.03 4.19 0.71
Effect of Exchange Rate Changes
- - - - - - - -0.01 0.00 -0.01 0.01

Quarterly Cash Flow Statements for Aethlon Medical

This table details how cash moves in and out of Aethlon Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
-2.72 -2.20 -2.53 3.63 -2.21 -2.03 0.69 -1.74 2.09 1.10 -1.93
Net Cash From Operating Activities
-2.70 -2.38 -2.57 -1.75 -2.21 -2.01 -1.67 -1.71 -1.66 -1.87 -1.75
Net Cash From Continuing Operating Activities
-2.70 -2.38 -2.56 -1.75 -2.21 -2.01 -1.67 -1.71 -1.66 -1.87 -1.75
Net Income / (Loss) Continuing Operations
-3.03 -3.47 -2.43 -2.57 -2.81 -1.75 -6.25 -1.76 -1.49 -2.02 -1.88
Consolidated Net Income / (Loss)
-3.03 -3.47 -2.43 -2.57 -2.81 -1.75 -6.25 -1.76 -1.49 -2.02 -1.88
Depreciation Expense
0.09 0.09 0.09 0.09 0.09 0.08 0.08 0.08 0.08 0.08 0.08
Non-Cash Adjustments To Reconcile Net Income
0.26 0.57 0.16 0.14 0.11 0.09 4.97 0.14 0.00 0.07 0.36
Changes in Operating Assets and Liabilities, net
-0.02 0.42 -0.38 0.60 0.25 -0.50 -0.26 -0.18 -0.40 -0.08 -0.08
Net Cash From Investing Activities
-0.01 -0.01 -0.00 0.00 - -0.00 0.00 0.00 - -0.00 -0.00
Net Cash From Continuing Investing Activities
-0.01 -0.01 -0.00 0.00 - -0.00 0.00 0.00 - -0.00 -0.00
Purchase of Property, Plant & Equipment
-0.01 -0.01 -0.00 - - - 0.00 - - - -0.00
Net Cash From Financing Activities
-0.01 0.18 0.04 5.38 -0.00 -0.01 2.36 -0.01 3.74 2.98 -0.20
Net Cash From Continuing Financing Activities
-0.01 0.18 0.04 5.38 -0.00 -0.01 2.36 -0.01 3.74 2.98 -0.20
Repurchase of Common Equity
- - - - - - -1.16 - - - -0.07
Issuance of Common Equity
- 0.19 0.05 5.38 - - -0.68 0.00 3.74 4.01 -0.85
Other Financing Activities, net
-0.01 -0.01 -0.01 -0.01 -0.00 -0.01 4.20 -0.01 -0.00 -0.00 0.72
Effect of Exchange Rate Changes
- - -0.00 -0.00 0.01 -0.01 -0.00 -0.02 0.01 -0.00 0.02

Annual Balance Sheets for Aethlon Medical

This table presents Aethlon Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets
2.53 1.73 7.35 4.12 10 11 19 18 8.25 7.36 6.33
Total Current Assets
2.38 1.60 7.23 4.04 10 10 18 15 6.23 5.95 5.57
Cash & Equivalents
2.12 1.56 6.97 3.83 9.60 9.86 17 15 5.44 5.50 5.03
Prepaid Expenses
0.05 0.04 0.18 0.21 0.23 0.34 0.96 0.56 0.51 0.45 0.33
Other Current Assets
- - - - - - - 0.00 0.28 0.00 0.21
Plant, Property, & Equipment, net
0.04 0.03 0.03 0.01 0.14 0.16 0.44 1.14 1.02 0.68 0.36
Total Noncurrent Assets
0.12 0.10 0.09 0.08 0.21 0.16 0.82 1.27 1.00 0.73 0.41
Intangible Assets
0.09 0.08 0.08 0.07 0.06 0.06 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets
0.02 0.01 0.02 0.01 0.15 0.10 0.82 1.27 1.00 0.73 0.41
Total Liabilities & Shareholders' Equity
2.53 1.73 7.35 4.12 10 11 19 18 8.25 7.36 6.33
Total Liabilities
1.03 1.13 1.32 1.82 1.11 1.38 2.43 2.44 2.48 2.24 1.45
Total Current Liabilities
0.53 0.61 0.48 1.82 1.07 1.38 1.82 1.51 1.83 1.90 1.45
Accounts Payable
0.39 0.54 0.21 0.22 0.40 0.46 0.50 0.43 0.78 0.53 0.38
Other Current Liabilities
0.14 0.07 0.26 0.65 0.57 0.80 0.98 1.07 1.05 1.36 1.06
Total Noncurrent Liabilities
0.50 0.52 0.84 0.00 0.04 0.00 0.60 0.94 0.65 0.34 0.00
Other Noncurrent Operating Liabilities
- - - 0.00 0.04 0.00 0.60 0.94 0.65 0.34 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1.50 0.60 6.03 2.30 9.28 9.29 17 15 5.77 5.12 4.89
Total Preferred & Common Equity
1.55 0.68 6.13 2.43 9.41 9.43 17 15 5.77 5.12 4.89
Total Common Equity
1.55 0.68 6.13 2.43 9.41 9.43 17 15 5.77 5.12 4.89
Common Stock
88 94 106 108 121 129 147 157 160 173 180
Retained Earnings
-87 -94 -99 -106 -112 -120 -130 -142 -155 -168 -175
Accumulated Other Comprehensive Income / (Loss)
- - - - - - 0.00 -0.01 -0.01 -0.02 -0.03

Quarterly Balance Sheets for Aethlon Medical

This table presents Aethlon Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 6/30/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025
Total Assets
13 10 11 8.85 6.53 5.31 7.32 8.06
Total Current Assets
10 8.25 9.55 7.14 4.97 4.05 6.25 7.14
Cash & Equivalents
10 7.97 9.07 6.86 4.83 3.77 5.85 6.96
Prepaid Expenses
0.31 0.28 0.48 0.28 0.09 0.28 0.18 0.19
Plant, Property, & Equipment, net
1.20 1.11 0.93 0.84 0.76 0.59 0.51 0.43
Total Noncurrent Assets
1.05 1.07 0.85 0.87 0.79 0.66 0.56 0.48
Intangible Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets
1.05 1.07 0.85 0.86 0.79 0.66 0.55 0.48
Total Liabilities & Shareholders' Equity
13 10 11 8.85 6.53 5.31 7.32 8.06
Total Liabilities
2.51 2.83 2.70 2.83 2.19 1.88 1.58 1.34
Total Current Liabilities
1.71 2.10 2.13 2.33 1.77 1.63 1.40 1.26
Accounts Payable
0.68 0.69 1.07 0.92 0.61 0.57 0.57 0.47
Other Current Liabilities
1.03 1.41 1.06 1.31 1.09 1.06 0.83 0.79
Total Noncurrent Liabilities
0.80 0.72 0.57 0.50 0.42 0.26 0.17 0.09
Other Noncurrent Operating Liabilities
0.80 0.72 0.57 0.50 0.42 0.26 0.17 0.09
Total Equity & Noncontrolling Interests
10 7.61 8.71 6.02 4.33 3.42 5.75 6.71
Total Preferred & Common Equity
10 7.61 8.71 6.02 4.33 3.42 5.75 6.71
Total Common Equity
10 7.61 8.71 6.02 4.33 3.42 5.75 6.71
Common Stock
159 160 166 166 166 173 177 180
Retained Earnings
-149 -152 -157 -160 -162 -170 -171 -173
Accumulated Other Comprehensive Income / (Loss)
-0.01 -0.00 -0.01 -0.00 -0.02 -0.02 -0.03 -0.03

Annual Metrics And Ratios for Aethlon Medical

This table displays calculated financial ratios and metrics derived from Aethlon Medical's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding
7,622,393.00 7,961,923.00 16,580,326.00 18,960,505.00 9,256,249.00 12,123,524.00 15,408,231.00 22,969,349.00 2,620,399.00 14,457,096.00 1,315,110.00
DEI Adjusted Shares Outstanding
635.00 663.00 1,382.00 1,580.00 11,570.00 15,154.00 19,260.00 28,712.00 32,755.00 180,714.00 1,315,110.00
DEI Earnings Per Adjusted Shares Outstanding
-7,672.96 -10,974.53 -4,109.67 -3,920.71 -550.90 -520.44 -540.81 -418.98 -372.71 -74.08 -5.44
Growth Metrics
- - - - - - - - - - -
Revenue Growth
16.28% -55.78% -100.00% 0.00% 183.15% 1.37% -55.37% 95.21% -100.00% 0.00% 0.00%
EBITDA Growth
-10.59% -61.69% 24.41% -24.94% 0.43% -34.86% -31.15% -14.59% -4.22% -8.53% 47.66%
EBIT Growth
-16.21% -46.97% 23.01% -20.92% 2.00% -34.24% -32.05% -15.54% -5.11% -8.14% 46.59%
NOPAT Growth
-9.82% -39.08% 20.78% -24.17% 1.15% -33.08% -32.05% -14.18% -6.20% 26.08% 21.92%
Net Income Growth
28.95% -47.35% 21.99% -9.12% -2.58% -23.69% -32.05% -15.44% -1.48% -9.67% 46.58%
EPS Growth
45.90% -42.42% 89.36% -5,030.00% 63.55% 65.24% 0.00% 0.00% -1.48% -9.67% 87.63%
Operating Cash Flow Growth
14.70% 23.07% -17.41% -9.79% -21.06% 160.48% -410.72% -7.56% 3.57% 24.52% 8.46%
Free Cash Flow Firm Growth
79.10% -31.63% 5.53% -0.16% -17.62% -20.34% -47.28% -14.91% 3.38% 32.43% 8.46%
Invested Capital Growth
-147.49% -267.14% 77.50% -466.00% 42.23% -73.48% 85.73% 755.73% -38.95% -216.46% 62.89%
Revenue Q/Q Growth
0.69% -34.30% -100.00% 406.93% -3.40% -20.74% -6.70% 4,278.20% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth
1.57% -7.35% 2.32% -5.83% -2.99% -6.50% -17.13% 9.37% -0.18% -40.76% 0.77%
EBIT Q/Q Growth
1.04% -6.94% 4.49% -5.63% -2.49% -6.48% -17.08% 8.83% -0.22% -39.32% 0.80%
NOPAT Q/Q Growth
1.04% -7.36% 4.61% -5.63% -3.39% -6.48% -17.08% 9.91% -0.07% 4.91% 1.01%
Net Income Q/Q Growth
-10.53% -6.35% 6.05% -5.42% -2.23% -6.47% -17.09% 9.88% 0.34% -40.06% 37.93%
EPS Q/Q Growth
-32.00% -9.30% 75.00% -5.12% 13.43% -6.56% 0.00% 9.88% 0.34% -40.06% 24.21%
Operating Cash Flow Q/Q Growth
15.53% 10.97% -20.45% -0.39% -4.48% 151.14% -1,075.16% 1.43% 3.63% 10.46% -1.12%
Free Cash Flow Firm Q/Q Growth
28.45% -1.93% -4.63% -8.23% 2.08% -11.35% -9.71% -0.92% 0.70% 13.48% 1.15%
Invested Capital Q/Q Growth
-13.01% -108.83% 49.03% 21.60% -28.64% 18.57% -149.16% 341.11% 189.91% 23.10% 42.38%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 0.00% -1,242.67% -254.14% -424.19% -1,472.52% 100.00% 0.00% 0.00% 0.00%
EBITDA Margin
-431.90% -1,579.13% 0.00% -2,546.40% -895.46% -1,191.25% -3,500.48% -2,054.85% 0.00% 0.00% 0.00%
Operating Margin
-494.58% -1,555.41% 0.00% -2,612.53% -912.04% -1,197.31% -3,542.53% -2,072.05% 0.00% 0.00% 0.00%
EBIT Margin
-494.58% -1,643.62% 0.00% -2,612.53% -904.17% -1,197.31% -3,542.53% -2,096.80% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-559.30% -1,863.61% 0.00% -2,708.55% -981.26% -1,197.31% -3,542.53% -2,094.89% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.99% 100.00% 99.98%
Interest Burden Percent
113.09% 113.38% 114.89% 103.68% 108.53% 100.00% 100.00% 99.91% 96.47% 97.82% 97.86%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,699.76% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,676.34% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,624.70% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-460.46% -696.62% -171.99% -149.29% -110.22% -84.99% -79.29% -75.06% -117.21% -245.88% -142.89%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,683.02% -2,019.28% 0.00% 0.00%
Operating Return on Assets (OROA)
-224.31% -302.87% 0.00% -104.56% -81.03% -74.96% -69.27% -65.21% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-253.66% -343.40% 0.00% -108.40% -87.94% -74.96% -69.27% -65.15% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-463.55% -740.22% -176.72% -153.37% -112.68% -86.22% -80.13% -75.39% -117.21% -245.88% -142.89%
Return on Equity Simple (ROE_SIMPLE)
-319.35% -1,080.27% -92.92% -256.46% -67.80% -83.68% -60.82% -79.86% -211.71% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.07 -4.27 -3.38 -4.20 -4.15 -5.52 -7.29 -8.33 -8.85 -6.54 -5.11
NOPAT Margin
-346.21% -1,088.79% 0.00% -1,828.77% -638.43% -838.12% -2,479.77% -1,450.43% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-162.59% -228.06% -64.63% -44.90% -35.75% -24.32% -23.21% -23.42% -33.67% -125.18% -38.87%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -153.40% -127.63% -104.49%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 1,342.67% 354.14% 524.19% 1,572.52% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
359.60% 767.99% 0.00% 1,369.85% 657.90% 773.12% 2,070.01% 1,398.24% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
594.58% 1,655.41% 0.00% 1,369.85% 657.90% 773.12% 2,070.01% 2,172.05% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-4.38 -6.44 -4.96 -6.00 -5.88 -7.89 -10 -12 -13 -14 -7.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.83 -6.19 -4.68 -5.85 -5.82 -7.85 -10 -12 -12 -13 -6.99
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.58 0.76 1.01 0.59
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.58 0.76 1.01 0.59
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.30 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.33 0.87 0.14 0.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.33 0.87 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.08 -1.27 -1.08 -1.08 -1.08 -1.05 -1.02 -0.99 -0.96 -1.00 -1.05
Leverage Ratio
1.82 2.03 1.37 1.38 1.25 1.13 1.14 1.15 1.24 1.43 1.37
Compound Leverage Factor
2.05 2.30 1.57 1.43 1.36 1.13 1.14 1.15 1.19 1.40 1.34
Debt to Total Capital
24.98% 46.58% 12.24% 29.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 29.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
24.98% 46.58% 12.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-2.51% -7.26% -1.47% -3.86% -1.42% -1.47% -0.83% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
77.54% 60.68% 89.24% 74.36% 101.42% 101.47% 100.83% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.13 -0.08 -0.18 -0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.42 0.17 1.31 0.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
-0.13 -0.08 -0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.16 -0.12 -0.25 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.53 0.24 1.81 0.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
-0.16 -0.12 -0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.53 -29.60 -36.04 -40.54
Noncontrolling Interest Sharing Ratio
-0.67% -6.26% -2.75% -2.73% -2.23% -1.45% -1.06% -0.44% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.51 2.61 15.13 2.21 9.40 7.53 9.95 10.03 3.40 3.13 3.85
Quick Ratio
4.41 2.55 14.75 2.10 9.19 7.28 9.43 9.66 2.97 2.90 3.47
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.00 -3.94 -3.73 -3.73 -4.39 -5.28 -7.78 -8.94 -8.64 -5.84 -5.34
Operating Cash Flow to CapEx
-46,516.68% 0.00% -15,754.26% 0.00% -3,427.03% 5,249.35% -2,797.07% -1,113.88% -4,037.92% 0.00% -188,941.47%
Free Cash Flow to Firm to Interest Expense
-5.22 -4.57 -5.05 -16.93 -8.76 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-7.55 -3.86 -5.30 -19.47 -10.37 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-7.56 -3.84 -5.33 -19.47 -10.67 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.45 0.18 0.00 0.04 0.09 0.06 0.02 0.03 0.00 0.00 0.00
Accounts Receivable Turnover
4.51 0.00 0.00 0.00 0.00 3.70 2.12 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
19.25 12.02 0.00 13.68 8.88 4.37 0.98 0.72 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 14.33 7.52 8.10 9.68 0.00 8.60 5.90 6.07
Days Sales Outstanding (DSO)
80.86 0.00 0.00 0.00 0.00 98.52 171.88 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 25.48 48.53 45.05 37.72 0.00 42.44 61.82 60.16
Cash Conversion Cycle (CCC)
80.86 0.00 0.00 -25.48 -48.53 53.47 134.16 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.12 -0.45 -0.10 -0.57 -0.33 -0.57 -0.08 0.53 0.32 -0.38 -0.14
Invested Capital Turnover
-10.42 -1.38 0.00 -0.69 -1.45 -1.47 -0.91 2.55 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.07 -0.32 0.34 -0.47 0.24 -0.24 0.49 0.61 -0.21 -0.70 0.24
Enterprise Value (EV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.75 -1.04 -0.33 -2.15
Market Capitalization
0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.79 4.40 5.18 2.88
Book Value per Share
$0.20 $0.09 $0.37 $0.13 $1.02 $0.78 $1.11 $0.66 $2.20 $0.35 $3.72
Tangible Book Value per Share
$0.19 $0.07 $0.37 $0.12 $1.01 $0.77 $1.11 $0.66 $2.20 $0.35 $3.72
Total Capital
2.00 1.11 6.87 3.26 9.28 9.29 17 15 5.77 5.12 4.89
Total Debt
0.50 0.52 0.84 0.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.50 0.52 0.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-1.62 -1.04 -6.13 -2.87 -9.60 -9.86 -17 -15 -5.44 -5.50 -5.03
Capital Expenditures (CapEx)
0.01 -0.02 0.02 0.00 0.15 0.06 0.35 0.94 0.25 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.27 -0.57 -0.22 -0.65 -0.63 -0.89 -0.74 -0.95 -1.05 -1.45 -0.90
Debt-free Net Working Capital (DFNWC)
1.85 0.99 6.75 3.18 8.97 8.98 16 14 4.40 4.05 4.12
Net Working Capital (NWC)
1.85 0.99 6.75 2.21 8.97 8.98 16 14 4.40 4.05 4.12
Net Nonoperating Expense (NNE)
1.89 3.04 2.32 2.02 2.23 2.37 3.13 3.70 3.36 6.85 2.05
Net Nonoperating Obligations (NNO)
-1.62 -1.04 -6.13 -2.87 -9.60 -9.86 -17 -15 -5.44 -5.50 -5.03
Total Depreciation and Amortization (D&A)
0.56 0.25 0.28 0.15 0.06 0.04 0.12 0.24 0.36 0.34 0.32
Debt-free, Cash-free Net Working Capital to Revenue
-30.89% -146.45% 0.00% -283.74% -97.11% -134.28% -251.38% -164.99% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
208.66% 251.36% 0.00% 1,383.36% 1,380.12% 1,361.93% 5,552.31% 2,365.80% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
208.66% 251.36% 0.00% 964.28% 1,380.12% 1,361.93% 5,552.31% 2,365.80% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.66) ($0.94) ($0.46) ($0.07) ($1.87) ($0.65) ($0.71) $0.00 ($38.88) ($85.80) ($10.61)
Adjusted Weighted Average Basic Shares Outstanding
7.62M 8.87M 17.76M 19.10M 12.05M 15.37M 15.83M 2.48M 314.10K 156.08K 673.95K
Adjusted Diluted Earnings per Share
($0.66) ($0.94) ($0.46) ($0.07) ($1.87) ($0.65) ($0.71) $0.00 ($38.88) ($85.80) ($10.61)
Adjusted Weighted Average Diluted Shares Outstanding
7.62M 8.87M 17.76M 19.10M 12.05M 15.37M 15.83M 2.48M 314.10K 156.08K 673.95K
Adjusted Basic & Diluted Earnings per Share
($0.66) ($0.94) ($0.46) ($0.07) ($1.87) ($0.65) ($0.71) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
7.39M 7.76M 12.32M 18.12M 3.41M 12.09M 14.76M 2.48M 1.74M 258.53K 2.37M
Normalized Net Operating Profit after Tax (NOPAT)
-3.07 -4.27 -3.38 -4.20 -4.15 -5.52 -7.29 -8.33 -8.85 -6.54 -5.11
Normalized NOPAT Margin
-346.21% -1,088.79% 0.00% -1,828.77% -638.43% -838.12% -2,479.77% -1,450.43% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-559.30% -1,863.61% 0.00% -2,708.55% -981.26% -1,197.31% -3,542.53% -2,094.89% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-7.64 -7.47 -6.72 -27.21 -11.73 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-5.35 -4.95 -4.58 -19.05 -8.28 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-7.66 -7.45 -6.75 -27.21 -12.03 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-5.37 -4.93 -4.61 -19.05 -8.58 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -4.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.69% -15.21%

Quarterly Metrics And Ratios for Aethlon Medical

This table displays calculated financial ratios and metrics derived from Aethlon Medical's official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
24,835,321.00 2,492,908.00 2,620,399.00 13,899,725.00 13,937,327.00 13,961,998.00 14,457,096.00 2,585,316.00 2,598,711.00 - 1,315,110.00
DEI Adjusted Shares Outstanding
31,044.00 31,161.00 32,755.00 173,747.00 174,217.00 174,525.00 180,714.00 258,532.00 259,871.00 - 1,315,110.00
DEI Earnings Per Adjusted Shares Outstanding
-97.75 -111.23 -74.05 -14.80 -16.11 -10.05 -34.61 -6.81 -5.72 - -1.43
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
18.94% -21.68% -0.09% 23.58% 8.87% 52.12% 20.01% 32.34% 49.01% -14.84% 3.65%
EBIT Growth
16.54% -24.89% -0.34% 23.08% 8.79% 49.01% 19.40% 31.41% 47.77% -13.63% 3.71%
NOPAT Growth
13.37% -25.17% -0.34% 23.10% 8.60% 49.13% 19.40% 31.61% 47.97% -13.63% 3.71%
Net Income Growth
20.30% -21.63% 1.67% 21.65% 7.50% 49.37% -157.89% 31.48% 47.02% -15.01% 69.88%
EPS Growth
0.00% 0.00% 1.67% 21.65% 7.50% 49.37% -157.89% 69.20% 47.02% 75.62% 93.01%
Operating Cash Flow Growth
13.46% -21.87% 12.94% 29.60% 18.11% 15.44% 34.80% 1.87% 25.10% 6.79% -4.65%
Free Cash Flow Firm Growth
4.62% -46.40% 34.66% 36.20% 50.16% 51.63% 54.32% 1.95% -57.57% -48.39% -126.71%
Invested Capital Growth
0.00% -63.73% -38.95% 0.00% -1,602.14% -36.16% -216.46% 23.62% 87.20% 50.47% 62.89%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
6.98% -12.35% 30.79% -5.65% -10.92% 40.97% -15.63% 10.63% 16.42% -32.96% 2.98%
EBIT Q/Q Growth
6.76% -12.00% 30.15% -5.46% -10.55% 37.39% -10.41% 10.25% 15.82% -36.22% 6.44%
NOPAT Q/Q Growth
6.83% -12.34% 30.31% -5.43% -10.73% 37.47% -10.41% 10.54% 15.76% -36.58% 6.44%
Net Income Q/Q Growth
7.55% -14.23% 30.03% -6.02% -9.16% 37.48% -256.45% 71.83% 15.59% -35.72% 6.64%
EPS Q/Q Growth
7.55% -12.30% 30.03% -6.02% -9.16% 37.48% -256.45% 78.80% 15.59% 34.49% -14.29%
Operating Cash Flow Q/Q Growth
-8.93% 12.07% -7.89% 31.88% -26.72% 9.20% 16.82% -2.53% 3.28% -13.00% 6.61%
Free Cash Flow Firm Q/Q Growth
-4.79% -3.42% 34.94% 9.52% 18.15% -0.38% 38.55% -94.20% -31.54% 5.47% 6.11%
Invested Capital Q/Q Growth
0.00% -745.15% 189.91% -237.90% -87.80% 41.52% 23.10% 9.55% 68.53% -126.29% 42.38%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
99.92% 100.23% 99.74% 99.97% 100.14% 100.00% 99.95% 100.00% 99.73% 100.00% 100.15%
Interest Burden Percent
95.57% 97.16% 97.82% 98.12% 96.72% 96.70% 312.33% 97.97% 98.50% 97.87% 97.52%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -98.43% -117.21% -105.38% -137.96% -160.04% -245.88% -207.29% -191.39% -208.60% -142.89%
Cash Return on Invested Capital (CROIC)
-30,020.55% 0.00% -2,019.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% -98.43% -117.21% -105.38% -137.96% -160.04% -245.88% -207.29% -191.39% -208.60% -142.89%
Return on Equity Simple (ROE_SIMPLE)
-112.73% -160.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.22 -2.50 -1.74 -1.83 -2.03 -1.27 -1.40 -1.25 -1.06 -1.44 -1.35
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-15.82% -7.61% -6.86% -16.09% -9.06% -7.57% -88.68% -7.85% -6.77% -9.76% -10.14%
Return On Investment Capital (ROIC_SIMPLE)
- -32.81% -30.18% -21.06% -33.75% -29.31% -27.37% -36.65% -18.39% -21.50% -27.64%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.18 -3.56 -2.49 -2.62 -2.90 -1.81 -2.00 -1.80 -1.51 -2.06 -1.93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.09 -3.47 -2.40 -2.54 -2.81 -1.66 -1.92 -1.72 -1.43 -1.91 -1.85
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.54 0.72 0.76 0.80 1.08 2.77 1.01 0.91 0.34 0.31 0.59
Price to Tangible Book Value (P/TBV)
0.54 0.72 0.76 0.80 1.08 2.77 1.01 0.91 0.34 0.31 0.59
Price to Revenue (P/Rev)
9.77 9.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.99 -1.02 -0.96 -0.42 -1.05 -1.07 -1.00 -1.07 -1.08 -1.07 -1.05
Leverage Ratio
1.24 1.25 1.24 1.25 1.33 1.42 1.43 1.38 1.37 1.32 1.37
Compound Leverage Factor
1.19 1.22 1.21 1.22 1.28 1.37 4.48 1.35 1.35 1.29 1.33
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-14.84 -19.61 -25.53 -17.71 -24.36 -31.73 -30.80 -44.36 -31.88 -29.13 -37.74
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
6.13 3.93 3.40 4.49 3.06 2.80 3.13 2.49 4.45 5.68 3.85
Quick Ratio
5.95 3.80 2.97 4.26 2.94 2.72 2.90 2.31 4.17 5.53 3.47
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.28 -2.36 -1.53 -1.39 -1.14 -1.14 -0.70 -1.36 -1.79 -1.69 -1.59
Operating Cash Flow to CapEx
-39,943.07% -26,999.38% -52,281.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -85,342.81%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.04 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.48 0.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.25 1.88 8.60 5.58 6.87 6.47 5.90 3.20 2.47 4.09 6.07
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
1,453.31 194.36 42.44 65.39 53.16 56.39 61.82 114.24 148.07 89.30 60.16
Cash Conversion Cycle (CCC)
-1,453.31 -194.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.06 -0.36 0.32 -0.45 -0.84 -0.49 -0.38 -0.34 -0.11 -0.24 -0.14
Invested Capital Turnover
20.54 -1.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.06 -0.14 -0.21 -0.45 -0.90 -0.13 -0.70 0.11 0.73 0.25 0.24
Enterprise Value (EV)
-4.66 -2.51 -1.04 -2.23 -0.36 7.18 -0.33 -0.66 -3.91 -4.85 -2.15
Market Capitalization
5.61 5.46 4.40 6.93 6.50 12 5.18 3.10 1.95 2.11 2.88
Book Value per Share
$0.42 $3.05 $2.20 $0.63 $0.43 $0.31 $0.35 $1.32 $2.21 $8.82 $3.72
Tangible Book Value per Share
$0.42 $3.05 $2.20 $0.63 $0.43 $0.31 $0.35 $1.32 $2.21 $8.82 $3.72
Total Capital
10 7.61 5.77 8.71 6.02 4.33 5.12 3.42 5.75 6.71 4.89
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-10 -7.97 -5.44 -9.16 -6.86 -4.83 -5.50 -3.77 -5.85 -6.96 -5.03
Capital Expenditures (CapEx)
0.01 0.01 0.00 0.00 0.00 0.00 -0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.49 -1.82 -1.05 -1.74 -2.05 -1.63 -1.45 -1.34 -1.00 -1.07 -0.90
Debt-free Net Working Capital (DFNWC)
8.78 6.15 4.40 7.42 4.81 3.19 4.05 2.42 4.85 5.88 4.12
Net Working Capital (NWC)
8.78 6.15 4.40 7.42 4.81 3.19 4.05 2.42 4.85 5.88 4.12
Net Nonoperating Expense (NNE)
0.81 0.97 0.69 0.74 0.78 0.48 4.85 0.51 0.43 0.57 0.53
Net Nonoperating Obligations (NNO)
-10 -7.97 -5.44 -9.16 -6.86 -4.83 -5.50 -3.77 -5.85 -6.96 -5.03
Total Depreciation and Amortization (D&A)
0.09 0.09 0.09 0.09 0.09 0.15 0.08 0.08 0.08 0.16 0.08
Debt-free, Cash-free Net Working Capital to Revenue
-258.89% -317.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
1,528.40% 1,070.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
1,528.40% 1,070.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($61.76) ($2.72) ($16.00) ($10.40) ($3,205.60) ($0.85) ($3.74) ($2.45) ($2.80)
Adjusted Weighted Average Basic Shares Outstanding
2.49M 2.62M 39.26K 932.24K 174.22K 174.53K 1.95K 2.08M 397.51K 823.13K 673.95K
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($61.76) ($2.72) ($16.00) ($10.40) ($3,205.60) ($0.85) ($3.74) ($2.45) ($2.80)
Adjusted Weighted Average Diluted Shares Outstanding
2.49M 2.62M 39.26K 932.24K 174.22K 174.53K 1.95K 2.08M 397.51K 823.13K 673.95K
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($61.76) $0.00 $0.00 $0.00 ($3,205.60) $0.00 $0.00 $0.00 ($2.80)
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.49M 2.62M 1.74M 1.74M 174.53K 180.71K 32.32K 2.60M 761.32K 1.32M 2.37M
Normalized Net Operating Profit after Tax (NOPAT)
-2.22 -2.50 -1.74 -1.83 -2.03 -1.27 -1.40 -1.25 -1.06 -1.44 -1.35
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.69% 0.00% 0.00% 0.00% -15.21%

Financials Breakdown Chart

Key Financial Trends

Aethlon Medical (NASDAQ:AEMD) continues to operate without revenue in the reported periods. Total revenue was $0 in each available quarterly income statement, while the company incurred recurring costs of revenue and operating expenses. This resulted in persistent operating and net losses, although the size of the quarterly losses generally improved during fiscal 2026 compared with the larger losses reported in late 2024 and early 2025.

  • Quarterly losses moderated from prior peaks. Net loss declined from $6.25 million in Q4 2025 to $1.76 million in Q1 2026, $1.49 million in Q2, $2.02 million in Q3 and $1.88 million in Q4. The latest loss remains substantial, but it is below the $2.4 million to $3.5 million quarterly losses reported during much of 2024.
  • Operating cash burn has shown some improvement. Net cash used in operating activities was approximately $2.7 million in Q2 2024, $2.4 million in Q3 2024 and $1.7 million in Q1 2025. The latest quarters remained comparatively better, with operating cash outflows of $1.66 million, $1.87 million and $1.75 million in Q2, Q3 and Q4 2026, respectively.
  • Liquidity remains stronger than near-term liabilities. At December 31, 2025, Aethlon reported $6.96 million of cash and equivalents against $1.26 million of current liabilities. Total current assets of $7.14 million were approximately 5.7 times current liabilities, providing a meaningful short-term liquidity cushion.
  • Capital expenditures are limited. Investing cash flows were close to breakeven in the latest quarters, and Q4 2026 capital spending was only $2,051. This limits the amount of cash required for property and equipment investment while the company remains in development mode.
  • Financing has repeatedly supported the cash balance. Aethlon raised approximately $5.4 million through common-equity issuance in Q1 2025, $3.7 million in Q2 2026 and $4.0 million in Q3 2026. These financings helped cash increase from $3.77 million at June 30, 2025, to $6.96 million at December 31, 2025, but they represent external funding rather than internally generated cash.
  • Cost trends are mixed. Cost of revenue declined from $1.92 million in Q3 2024 to $1.21 million in Q4 2026, while selling, general and administrative expense generally remained between $1.2 million and $1.5 million per quarter. However, because revenue remained at zero, the lower expenses have not translated into gross profit or operating profitability.
  • The company has not demonstrated a revenue-generating business. Zero reported revenue across the available periods means Aethlon remains dependent on financing, partnerships or future commercialization to fund operations. There is no current revenue base against which investors can assess growth or operating leverage.
  • Operating losses and negative operating cash flow remain persistent. Aethlon has reported a net loss in every supplied quarter, and operating activities consumed cash in every supplied period. At the Q4 2026 operating cash-burn rate of approximately $1.75 million per quarter, the December cash balance would cover only a limited number of quarters before additional funding may be needed, assuming no improvement in operations.
  • Shareholder dilution is a recurring funding risk. The company has relied heavily on common-equity issuance to offset operating cash losses. The common-stock balance increased from $159.8 million at December 31, 2023, to approximately $180.0 million at December 31, 2025, while reported share counts vary substantially across periods because of apparent capital-structure changes and restatements. Future equity raises could reduce existing shareholders’ ownership and per-share value.
  • Retained earnings remain deeply negative. Retained earnings were negative $173.2 million at December 31, 2025, reflecting substantial cumulative losses. Although total equity was positive at $6.7 million, the balance sheet remains dependent on paid-in capital and future financing rather than accumulated profits.

Overall, AEMD’s financial position has improved modestly from the sharp cash burn and larger losses seen in earlier periods, and its current liquidity appears adequate for the near term. However, the investment case remains highly speculative: the company has no reported revenue, continues to consume cash, has a large accumulated deficit and has repeatedly used equity financing to fund operations.

11/21/26 07:21 PM ETAI Generated. May Contain Errors.

Aethlon Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aethlon Medical's financial year ends in March. Their financial year 2026 ended on March 31, 2026.

Aethlon Medical's net income appears to be on a downward trend, with a most recent value of -$7.15 million in 2026, falling from -$4.96 million in 2016. The previous period was -$13.39 million in 2025. See Aethlon Medical's forecast for analyst expectations on what's next for the company.

Aethlon Medical's total operating income in 2026 was -$7.29 million, based on the following breakdown:
  • Total Gross Profit: -$2.79 million
  • Total Operating Expenses: $4.51 million

Over the last 10 years, Aethlon Medical's total revenue changed from $886.57 thousand in 2016 to $0.00 in 2026, a change of -100.0%.

In the past 9 quarters, Aethlon Medical's cash and equivalents has ranged from $3.77 million in Q1 2026 to $10.18 million in Q2 2024, and is currently $6.96 million as of their latest financial filing in Q3 2026.

Aethlon Medical had total debt of $0.00 at the end of 2026, compared with none in 2025, and a 100.0% decrease since 2016.

Over the last 10 years, Aethlon Medical's book value per share changed from 0.20 in 2016 to 3.72 in 2026, a change of 1,724.0%.



Financial statements for NASDAQ:AEMD last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners